Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

To investigate the prevalence and clinical relevance of Helicobacter Pylori (HP) in chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) and without nasal polyps (CRSSNP). Three investigators ...

Roshni Naik, MD, allergist at Mount Sinai Health System, discusses the results after treating a case of severe asthma with nasal polyps: "After five months of starting Dupilumab frequency of ...

Nucala has been approved to treat severe eosinophilic asthma for almost a decade, and in the interim has had its label extended to include chronic rhinosinusitis with nasal polyps, eosinophilic ...

The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

including chronic rhinosinusitis with nasal polyps and eosinophilic granulomatosis with polyangiitis. It has previously modelled peak sales for the new drug of around £3 billion a year.

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Dr. Ransom is a graduate of the University of Iowa College of Medicine (1962) and was certified by the American Board of Allergy and Immunology in 1974. He is a Fellow of the American College of ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...